Purpose: To assess short-term and longer-term effects of brivaracetam (BRV) on cognition and behavior in a naturalistic clinical setting. Methods: Analyses were based on 43 patients with epilepsy who had undergone a neuropsychological screening before adjunctive treatment with BRV and a follow-up evaluation either after 5 days or 25 weeks. The standard assessment focused on reaction times (Neurocog FX), attention and executive functions (EpiTrack), and verbal memory (short version of the VLMT). Self-perceived cognition and behavior was evaluated by an extended version of the Adverse Events Profile. In addition, health-related quality of life (QOLIE-10) was reassessed at the longer-term interval. Results: Repeated measures analysis of variance revealed a significant improvement under BRV with regard to attention and executive functions (p = .03) without an interaction with the length of the observation interval. A statistical trend in the same direction was also seen for the reaction times (p = .07), but not for the unchanged verbal memory performance. Subjective measures indicated improvements in concentration (p = .02) and especially in comprehension (p < .001), and health-related quality of life (p = .002). Mood and aggression scores were unchanged. At the longer-term follow-up, an at least 50 percent reduction in seizure frequency was observed in 53% of the patients, 21% were seizure free. Conclusion: These preliminary data point to a favorable cognitive profile of BRV similar to its precursor levetiracetam. Objective gains in attention and executive functions were accompanied by self-reported improvements in concentration and comprehension. Future studies with larger sample sizes and better control conditions are needed to confirm these findings. itoring of the cognitive and behavioral effects of drug treatment in inhttps://doi.
Introduction
Brivaracetam (BRV) was approved in 2016 as a new antiepileptic drug (AED) for the adjunctive pharmacological treatment of focal-onset seizures with or without secondary generalization. Meanwhile BRV was also approved as monotherapy. BRV is a derivative of levetiracetam (LEV) with a 15-to 30-fold higher affinity to ubiquitous synaptic vesicle glycoprotein 2A [1] .
A recent meta-analysis of randomized controlled trials on the adverse event profile of BRV reported a significant association between BRV treatment and dizziness, fatigue, and back pain without an obvious dose dependency [2] . Psychiatric problems were not found to be increased. In a preclinical model BRV treated rats showed no deviation in cognition and behavior compared to control rats, whereas LEV treated animals demonstrated significantly more aggressive and less social behaviors [3] . A favorable and superior adverse effect profile of BRV versus LEV was concluded. However, a more recent study found behavioral changes, predominantly aggressive behavior, in a relevant number of patients with intellectual disability and epilepsy treated with brivaracetam [4] .
Regarding cognition, no negative effects of BRV have been seen in animal models when investigating spatial learning and memory [5] . In an Alzheimer's disease mouse model even positive effects of BRV on spatial memory have been reported [6] .
Up to now only a single study has evaluated the neurocognitive effects of BRV in man, i.e. 16 healthy volunteers [7] . Objective and subjective cognition under BRV did not differ from placebo or treatment with LEV.
Up to now the objective cognitive effects of BRV have not been studied in people with epilepsy.
At the epilepsy center in Bonn we have established a routine mon-and outpatients that is following a natural schedule as requested by the treating physician [8, 9] . Data from these assessments were retrospectively examined in order to evaluate the short-term and longer-term effects of adjunctive BRV on cognition and behavior. Since BRV is a successor of LEV, we expected a comparable favorable cognitive profile. However, given that LEV may exert negative effects on mood and behavior [10, 11] , we also focused on behavioral side effects.
BRV is the very first antiepileptic drug (AED) that can provide an efficacious target dose already on titration day 1, offering the opportunity for exceptionally early cognitive follow-up evaluations.
Methods

Study design and participants
Retrospective analyses were based on 43 patients with epilepsy who had undergone a standardized cognitive screening before and after introduction of adjunctive treatment with BRV at our department. The follow-up evaluation was performed either after 5 ± 2 days (n = 24) or after 25 ± 13 weeks (n = 19). The demographic and clinical characteristics are presented in Table 1 . There were no significant differences between the two follow-up conditions. However, there was a nonsignificant trend of a higher total antiepileptic drug load 1 at the shortterm (vs. longer-term) follow-up (T=-1.9, p = .06; cf. Table 1 ). Concomitant AEDs and respective changes are listed in Table 2 . At baseline the by far most common AEDs were LEV (77%) and lamotrigine (LTG; 51%).
Neuropsychological assessments
Neuropsychological routine assessment focused on attention and executive functions (EpiTrack), and verbal memory (short version of the VLMT). In addition to our routine battery we also assessed psychomotor speed and alertness via reaction times (subtest of the NeuroCog FX). Self-perceived cognition and behavior was evaluated by an extended version of the Adverse Events Profile (AEP). In addition, health-related quality of life (QOLIE-10) was reassessed at the longer-term interval.
Reaction times
Simple reaction times on visual stimuli were measured via the respective subtest of the Neurocog FX, a computerized test battery developed for neurological settings and patients with epilepsy in particular [12, 13] . Every time a blue circle is presented on the screen patients had to push a key as fast as they could. The relevant parameter is the median reaction time in milliseconds. Neurocog FX provides normative data from 244 healthy controls and reliable change indices (RCIs) to determine significant intraindividual change. Regarding the simple reaction times, the cutoff for a significant increase or decrease is > 80 ms or < 80 ms, respectively.
Attention and executive function
The EpiTrack ® (second edition with extended and revised norms) is a screening tool devised for the tracking of adverse cognitive effects of antiepileptic medication [14, 15] . The test comprises six subtests on response inhibition, visuo-motor speed, mental flexibility, visual motor planning, verbal fluency and working memory. Based on the subtest results, an age-corrected total score is calculated. Application and evaluation of this test is simple and thus guarantees objectivity. Agecorrected norms from 689 healthy individuals (age range and RCIs for reassessments are provided. Patients can achieve a maximum score of 49 points. The interval for mild impairment is 29-31 points, and the cutoff for significant impairment is ≤28 points. Practice corrected RCIs indicate a significant change with a gain of > 3 points, and a loss of > 2 points. Studies demonstrated the usefulness of the Epi-Track with regard to cognitive monitoring of pharmacological treatments [8, 9, 16, 17] and its sensitivity in regard to the overall drug load, i.e. the number of concurrent AEDs [18] .
Verbal memory
Episodic memory was assessed via a short version of the Verbaler Lern-und Merkfähigkeitstest (VLMT) [19] , the German adaption of the Rey Auditory Verbal Learning Test (RAVLT) and the most commonly applied verbal learning and memory test in German epilepsy centers [20] . The applied version consists of two consecutive trials of learning and immediate recall of a 15-item word list before performing the EpiTrack. Delayed free recall of the learned items is requested after the EpiTrack. Thus the Epitrack represents the distraction condition for memory testing. Memory performance was normalized with results from 383 healthy individuals. Scores for learning (learning trials 1 + 2), memory (delayed recall trial 3), and loss of learned items over time (trial 2 minus trial 3) were converted into a scale ranging from 1 to 7 according to the norm data of the healthy subjects and merged into a total memory score ranging from (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . After age correction, total memory scores from 14 to 18 were rated as normal, scores from 11 to 13 as mild impairment, and scores of ≤10 as significant impairment. According to practice corrected RCI (p < .10) a change was considered to be significant with a gain of > 3 points and a loss of > 5 points. This short version of the VLMT had been applied together with EpiTrack in previous studies on the cognitive effects of LEV vs. carbamazepine (CBZ) monotherapy [16] , lacosamide (LCM) vs. topiramate (TPM) vs. lamotrigine (LTG) [9] , and perampanel (PER) vs. LCM [8] .
Side effects
Self-perceived side effects of AEDs were assessed by an extended version of the Adverse Events Profile (AEP) [9, 21] covering the three domains (1) cognition (vigilance, psychomotor speed, attention, fluent speech, word finding comprehension, remote memory, recent memory, spatial orientation), (2) behavior (energy, depression, anxiety, aggression, irritability), and (3) physical/physiological symptoms (vestibular disorder, dizziness, drowsiness, sleepiness, nervousness, tremor, headache, upset stomach/nausea, trouble with mouth or gums, hair loss, skin problems, double or blurred vision, weight gain or loss, sexual dysfunction, altered libido, disturbed sleep). Patients were asked to rate the presence and strength of impairments on a four-tiered scale ranging from not at all (0) to strong (3).
Health-related quality of life
Health-related quality of life was assessed via the German adaptation of the Quality of Life in Epilepsy (QOLIE)-10 questionnaire [9] which is a widely used and validated instrument developed specifically to screen aspects of health-related quality of life for individuals with epilepsy [22] . The QOLIE-10 covers different epilepsy-and treatmentrelated issues including energy, mood, mobility, work and social limitations, cognitive problems, physical and cognitive treatment effects, seizure worries, and general quality of life. In contrast to the original version, the German adaptation comprises 13 items. Each item includes a 5-tiered rating scale (1-5) so that total scores between 13 and 65 can be achieved with greater values reflecting worse quality of life. Since on item level values of 1 indicate no impairment, and values of 2 the mildest form of impairment, total scores exceeding half of the possible 1 The total antiepileptic drug load was quantified according to the defined daily doses (DDD) of concurrent AEDs. The DDD is provided by the Collaborating Centre for Drug Statistics Methodology of the World Health Organization (WHO) and reflects the "assumed average maintenance dose per day" for drugs used in different medical areas, in this context the treatment of epileptic seizures (http://www.whocc.no/atc_ddd_index/). Regarding individual patients, the actual daily dose of a specific AED is related to the respective DDD by calculating the respective ratio (daily dose/DDD). The cumulative or total DDD is the sum of this ratio for all AEDs of the individual regimen. maximum were arbitrarily defined as impaired quality of life (cutoff: ≥33). Change in quality of life was rated as significant when patients changed more than one standard deviation (> 11 points) with reference to a sample of 892 patients with epilepsy [9] .
Statistical analyses
Statistical evaluations were performed with the IBM SPSS 24 software package. All cognitive test parameters were transformed into standard values (M = 100, SD = 10) according to the respective normative data. Baseline characteristics of the two different follow-up conditions were compared by t-tests and frequency statistics (χ²) of categorical data.
Changes in objective test performance under BRV were evaluated by repeated measures analysis of variance with time as within-and length of the observation interval as between-subjects factor.
Individual level analyses considered (1) the percentage of patients with impairments at baseline according to normative data, and (2) patients with significant individual changes as defined by reliable change indices (RCI). After repeated measures analyses of variances in the total sample, changes in subjective ratings of treatment-related side effects were analyzed separately within each follow-up condition via t-tests for dependent measures. Changes in health-related quality of life were analyzed for the longer-term follow-up employing a t-test for dependent measures.
Results
Baseline
Baseline performances on a group (metric) and individual (categorial) level are presented in Table 3 .
At baseline, below average performance with regard to attention and executive function was seen in 72% of the total sample. Subaverage reaction times and verbal memory performance were registered in 41% and 71% of the patients; respectively. Despite more frequent below average reaction times in the subgroup that subsequently underwent the short-term interval (χ² = 4.4, p = .034), there were no significant baseline differences between patients with the short-vs. longer-term follow-up, neither on a metric nor on a categorial level ( Table 3 ). The baseline medication is summarized in Table 2 . Thirty-three patients (77%) were treated with LEV at baseline. Among these, 16 (48%) reported negative psychotropic side effects under LEV, while 9 (27%) registered no enhanced seizure control with LEV.
Reassessment
The reassessment was conducted either after 5 ± 2 days (n = 24) or after 25 ± 13 weeks (n = 19). The mean dose of BRV was not different at the short-vs. longer-term follow-up with 208.3 ± 81.7 mg/d and 210.5 ± 63.6 mg/d, respectively ( Table 1 ). The total antiepileptic drug load increased significantly from baseline to follow-up (F = 20.6, p < .001) irrespective of the length of the observation interval (F = 0.3, p = .57). The majority of patients (65%) were switched from LEV to BRV (Table 2 ). An additional 12% of patients were still on LEV 0 (0%) 0 (0%) 0 (0%) 1 (5%) Oxcarbazepine (OXC) 2 (8%) 2 (8%) 1 (5%) 0 (0%) Perampanel (PER) 3 (13%) 3 (13%) 1 (5%) 0 (0%) Phenytoin (PHT) 1 (4%) 2 (8%) 0 (0%) 0 (0%) Pregabalin (PGB) 0 (0%) 0 (0%) 1 (5%) 0 (0%) Primidone (PRM) 1 (4%) 0 (0%) 0 (0%) 0 (0%) Topiramate (TPM) 2 (8%) 2 (8%) 2 (11%) 2 (11%) Valproic acid (VPA) 4 (17%) 4 (17%) 4 (21%) 5 (26%) Zonisamide (ZNS) 5 (21%) 5 (21%) 2 (11%) 1 (5%) T1 = baseline; T2 = follow-up. at the short-term follow-up with ongoing withdrawal of LEV. Repeated measures analysis of variance revealed a significant improvement under adjunctive treatment with BRV (within-subjects factor) with regard to attention and executive functions (F = 4.8, p = 0.03) without an interaction with the length of the observation interval (between-subjects factor; F = 0.2, p = .66). A statistical trend in the same direction was also observed for the reaction times (F = 3.6, p = 0.07), but not for the unchanged verbal memory performance (F = 0.4, p = .54). Given that there were no interaction effects with the length of the observation interval, Fig. 1 illustrates the cognitive performance at baseline and follow-up for the total sample.
In line with the group analyses, significant individual improvements in attention and executive functions occurred more frequently than deteriorations (26% vs. 9%). Improvements were numerically higher after the longer-term reassessment as compared to the short follow-up (37% vs. 17%), but this difference did not reach statistical significance (χ² = 2.6, p = .278; see Table 3 ). Regarding the reaction times, there were no individual declines but improvements in 15% of the patients. No individual changes in verbal memory performance were registered (Table 3) . Repeated measures analyses on subjective measures indicated improvements in concentration (F = 5.6, p = 0.02; no interaction with the length of the observation interval: F = 0.8, p = .38) and especially in comprehension (F = 24.3, p < 0.001; more pronounced at the longer-term follow-up as indicated by an interaction effect: F = 4.7, p = .04). As shown in Table 3 , separate paired t-tests for the two observation intervals revealed further differential improvement in fluent speech at the short-term follow-up (T = 2.3, p = .04), and better spatial orientation at the longer-term reassessment (T = 2.5, p = .03). Mean scores for behavioral aspects including mood (F = 1.5, p = .23) and aggression (F = 0.2, p = .69) were entirely unchanged in the total sample as well as in the subgroup of patients with a complete switch from LEV to BRV (N = 28). Improvements were observed for physiological aspects as there were nervousness (T = 2.5, p = .02), tremor (T = 2.0, p < .05), and nausea (T = 2.1, p = .04), while significantly reduced drowsiness (T = 2.4, p = .03) was only found at the longerterm follow-up.
Health-related quality of life which was reassessed at the longerterm follow-up significantly improved (T = 3.8; p = .002). On an individual level, 20% improved and no patient reported a decreased health-related quality of life.
At the longer-term follow-up an at least 50 percent reduction in seizure frequency was noted in 53% of the patients, 21% were seizure free. Exploratory analyses correlating the seizure outcome (seizure free yes/no, responder yes/no, percent reduction in seizure frequency) to change in objective cognitive measures disclosed no significant correlations. However, the apparent low statistical power needs to be considered.
Discussion
This is the very first study evaluating the effects of adjunctive BRV on cognition and behavior in patients with epilepsy in a naturalistic clinical setting. Retrospective analyses were based on 43 patients with epilepsy who had undergone a neuropsychological screening before adjunctive treatment with brivaracetam and a follow-up evaluation either after 5 days or after 25 weeks.
Objective cognitive assessments indicated a significant improvement in attention and executive functions under adjunctive treatment with BRV, a non-significant trend of improved reaction times, and unchanged verbal memory performance. There was no significant outcome difference between the short-and longer-term follow-up. Individual level analyses resembled the results on the group level.
Therefore the objective cognitive outcome is promising with at least neutral or even potentially beneficial effects of adjunctive BRV. So far the results in patients with epilepsy are in line with the neurocognitive findings in healthy volunteers [7] . The cognitive profile of BRV seems to be similar to its precursor LEV. The current findings confirm the neutral effect of BRV on memory reported in animal models [5] , but does not find an objective positive effect on memory demonstrated in a Alzheimer's disease mouse model [6] . Visuospatial memory was not part of the routine screening, but interestingly the patients' subjective reports indicated an improvement in spatial orientation/memory under BRV.
The current study employed valid objective tests with extensive normative data providing retest norms. Therefore the cognitive change under adjunctive treatment with BRV was controlled against confidence intervals for change in a substantial number of healthy controls. Nevertheless, an additional control condition, i.e. another AED as comparator, would have been appreciated. However, an adequate comparator for the short-term follow-up is formally not available, since it is a unique characteristic of BRV that an efficacious target dose can already be established on day 1 of oral titration. This condition is exceptional since it offers the opportunity to check for side effects within short intervals, e.g. during an inpatient-stay. However, in the past we have gathered preliminary data on patients we had offered fast uptitration of topiramate (TPM) with 50 mg per day during their inpatient-stay in order to rapidly determine whether they tolerate TPM or not [23] . The introduction of adjunctive TPM was flanked by a cognitive monitoring using the EpiTrack [24] . The mean follow-up interval was also 5 days and the TPM end dose 215 mg/d. Of the 10 patients 70% showed a significant decline in attention and executive functions, while only one (10%) improved. In contrast 5 days after introduction of BRV 17% of the patients showed a significant improvement and only 8% a significant decline. These are striking (χ² = 14.0, p = .001) but to be expected differences in a comparable study design.
The longer-term outcome can be easily compared to previous studies from our department which have investigated the effects of other AEDs employing the same naturalistic study design and cognitive measures [8, 9] . Currently available comparators are LCM, LTG, TPM, and PER. Fig. 2 depicts the differential change in executive performance under these agents compared to BRV. Adjunctive treatment with BRV is associated with a small (> 0.2) positive effect size (Cohen's d = 0.31), while a rather neutral effect (positive effect sizes < 0.2) is seen for LCM (Cohen's d = 0.14), LTG (Cohen's d = 0.07), and PER (Cohen's d = 0.06). For TPM a medium (< −0.5) negative effect size (Cohen's d=−0.60) was observed. Furthermore, the effect size of adjunctive BRV is in the range of two non-interventional studies on the cognitive effects of LEV (Cohen's d ranging between 0.21-0.34 for change in EpiTrack performance) [16, 17] .
The outcome in subjective measures was quite positive with cognitive improvements reported primarily in concentration and comprehension. This may indeed reflect the subjective perception of the objective gains in attention and executive functions. Given the behavioral side effects of LEV [10, 11] , it is important to emphasize that there was no change in self-rated aggression and mood under adjunctive BRV. However, since diminished self-awareness of behavioral side effects cannot be totally excluded, future studies should also employ otherratings from the socio-environment of the patient. Caution may still be warranted. According to the rating by the patients some physiological aspects improved under BRV as there were nervousness, tremor, and nausea.
At the longer-term follow-up patients rated their health-related quality of life again indicating a significant gain under treatment with BRV compared to baseline.
Seizure outcome at the longer-term follow-up was promising with a responder rate of 53% and seizure freedom rate of 21%. Actually the numbers are higher than those reported in three larger postmarketing studies from German epilepsy centers [25] [26] [27] with responder rates is compared to other antiepileptic drugs that were all evaluated at the epilepsy center in Bonn using the same study design and cognitive measures (EpiTrack) [8, 9] . Positive effect sizes indicate improvement, negative effect sizes deterioration. An absolute value > 0.2 reflects a small effect, absolute values > 0.5 a medium effect, and absolute values > 0.8 a large effect. *, p < .05; **, p < .01; BRV, brivaracetam; LCM, lacosamide; LTG, lamotrigine; PER, perampanel; TPM, topiramate. ranging from 28 to 41% and seizure freedom rates ranging from 7 to 15%. Taking the small sample size into consideration, the current data on seizure outcome of BRV should not be overestimated.
Given that two large non-interventional studies [16, 17] attributed the positive cognitive effect of LEV to (a) LEV induced seizure control and (b) a potential stimulating effect of LEV, it would have been of interest to analyze the role of seizure outcome on the cognitive change under BRV. Unfortunately sample sizes were too small for such analyses and the exploratory correlation analysis did not reveal any linear relationship. This issue needs to be readdressed when more patients have been seen or in upcoming cognitive studies on BRV.
Further limitations of the current study design have been discussed before [8, 9] and include its retrospective nature, the limited representativity of the patients enrolled in a specialized epilepsy center, and the non-standardized follow-up intervals. Due to the naturalistic outpatient setting, the co-medication was not kept stable for some of the analyzed patients. Therefore it cannot be ruled out that some positive change may be also attributed to the withdrawal of co-medication. However, in many cases BRV was given in exchange to LEV, whereas TPM that is known for its in part severe adverse cognitive side effects [28, 29] remained unchanged during the study ( Table 2) .
Conclusion
These preliminary data point to a favorable cognitive profile of BRV similar to its precursor LEV. This is in line with results from healthy volunteers [7] . Objective gains in attention and executive functions were accompanied by self-reported improvements in concentration and comprehension. No changes in self-rated mood and/or aggression were indicated. Health-related quality of life improved and the seizure outcome at the longer-term follow-up appeared promising. The results underscore that antiepileptic pharmacotherapy may also have positive effects on cognition [30] .
Future studies with larger sample sizes, more comprehensive test diagnostics, and better control conditions are needed to confirm these findings.
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